drugset
drugset / Trial / NCT07244406

Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL

NCT07244406 ↗

Phase 2 Recruiting 59 enrolled Hebei Senlang Biotechnology Inc., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of S1904 in patients with relapsed or refractory CD19+B-ALL.

Timeline

Start
2025-01-10
Primary completion
2027-03-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject S1904 Cell therapy 1e+06 cells/kg Intravenous

Indications

No indication recorded.